1. Home
  2. CGEM vs SPOK Comparison

CGEM vs SPOK Comparison

Compare CGEM & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEM
  • SPOK
  • Stock Information
  • Founded
  • CGEM 2016
  • SPOK 2004
  • Country
  • CGEM United States
  • SPOK United States
  • Employees
  • CGEM N/A
  • SPOK N/A
  • Industry
  • CGEM Biotechnology: Pharmaceutical Preparations
  • SPOK Telecommunications Equipment
  • Sector
  • CGEM Health Care
  • SPOK Telecommunications
  • Exchange
  • CGEM Nasdaq
  • SPOK Nasdaq
  • Market Cap
  • CGEM 437.2M
  • SPOK 379.1M
  • IPO Year
  • CGEM 2021
  • SPOK 1992
  • Fundamental
  • Price
  • CGEM $8.49
  • SPOK $16.41
  • Analyst Decision
  • CGEM Strong Buy
  • SPOK
  • Analyst Count
  • CGEM 7
  • SPOK 0
  • Target Price
  • CGEM $26.00
  • SPOK N/A
  • AVG Volume (30 Days)
  • CGEM 1.5M
  • SPOK 111.2K
  • Earning Date
  • CGEM 11-07-2025
  • SPOK 10-29-2025
  • Dividend Yield
  • CGEM N/A
  • SPOK 7.63%
  • EPS Growth
  • CGEM N/A
  • SPOK 10.71
  • EPS
  • CGEM N/A
  • SPOK 0.83
  • Revenue
  • CGEM N/A
  • SPOK $140,742,000.00
  • Revenue This Year
  • CGEM N/A
  • SPOK $5.45
  • Revenue Next Year
  • CGEM N/A
  • SPOK $0.56
  • P/E Ratio
  • CGEM N/A
  • SPOK $19.73
  • Revenue Growth
  • CGEM N/A
  • SPOK 1.79
  • 52 Week Low
  • CGEM $5.68
  • SPOK $13.55
  • 52 Week High
  • CGEM $17.50
  • SPOK $19.31
  • Technical
  • Relative Strength Index (RSI)
  • CGEM 62.54
  • SPOK 49.80
  • Support Level
  • CGEM $7.69
  • SPOK $16.11
  • Resistance Level
  • CGEM $8.69
  • SPOK $16.45
  • Average True Range (ATR)
  • CGEM 0.65
  • SPOK 0.30
  • MACD
  • CGEM 0.06
  • SPOK 0.12
  • Stochastic Oscillator
  • CGEM 72.76
  • SPOK 95.35

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: